Literature DB >> 9871940

Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues.

T M Tzschentke1.   

Abstract

This review gives an overview of recent findings and developments in research on brain mechanisms of reward and reinforcement from studies using the place preference conditioning paradigm, with emphasis on those studies that have been published within the last decade. Methodological issues of the paradigm (such as design of the conditioning apparatus, biased vs unbiased conditioning, state dependency effects) are discussed. Results from studies using systemic and local (intracranial) drug administration, natural reinforcers, and non-drug treatments and from studies examining the effects of lesions are presented. Papers reporting on conditioned place aversion (CPA) experiments are also included. A special emphasis is put on the issue of tolerance and sensitization to the rewarding properties of drugs. Transmitter systems that have been investigated with respect to their involvement in brain reward mechanisms include dopamine, opioids, acetylcholine, GABA, serotonin, glutamate, substance P, and cholecystokinin, the motivational significance of which has been examined either directly, by using respective agonist or antagonist drugs, or indirectly, by studying the effects of these drugs on the reward induced by other drugs. For a number of these transmitters, detailed studies have been conducted to delineate the receptor subtype(s) responsible for the mediation of the observed drug effects, particularly in the case of dopamine, the opioids, serotonin and glutamate. Brain sites that have been implicated in the mediation of drug-induced place conditioning include the 'traditional' brain reward sites, ventral tegmental area and nucleus accumbens, but the medial prefrontal cortex, ventral pallidum, amygdala and the pedunculopontine tegmental nucleus have also been shown to play important roles in the mediation of place conditioning induced by drugs or natural reinforcers. Thus, although the paradigm has also been criticized because of some inherent methodological problems, it is clear that during the past decade place preference conditioning has become a valuable and firmly established and very widely used tool in behavioural pharmacology and addiction research.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9871940     DOI: 10.1016/s0301-0082(98)00060-4

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  342 in total

1.  Behavioral screening for cocaine sensitivity in mutagenized zebrafish.

Authors:  T Darland; J E Dowling
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

2.  Increased sensitivity to cocaine by cholinergic cell ablation in nucleus accumbens.

Authors:  T Hikida; S Kaneko; T Isobe; Y Kitabatake; D Watanabe; I Pastan; S Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

3.  Needed: mouse/human cross validation of reinstatement/relapse models (and drug reward models) to model human substance abuse vulnerability allelic variants.

Authors:  George R Uhl
Journal:  Psychopharmacology (Berl)       Date:  2003-04-29       Impact factor: 4.530

4.  Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse.

Authors:  J C Cole; H R Sumnall; E O'Shea; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  2003-02-25       Impact factor: 4.530

5.  Dopamine D1 and D3 receptors are differentially involved in cue-elicited cocaine seeking.

Authors:  Liping Chen; Ming Xu
Journal:  J Neurochem       Date:  2010-04-28       Impact factor: 5.372

6.  Enhanced tyrosine hydroxylase phosphorylation in the nucleus accumbens and nucleus tractus solitarius-A2 cell group after morphine-conditioned place preference.

Authors:  A González-Cuello; L Mora; J M Hidalgo; N Meca; C Lasheras; M V Milanés; M L Laorden
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-10-06       Impact factor: 3.000

7.  The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.

Authors:  Richard B Silverman
Journal:  J Med Chem       Date:  2012-01-10       Impact factor: 7.446

8.  Role of Nicotinamide N-Methyltransferase in Dorsal Striatum in Cocaine Place Preference.

Authors:  Li Luo; Fei-Fei Shang; Hailei Long; Linhong Jiang; Ruiming Zhu; Qian Zhao; Hui Gu; Jueying Kong; Wei Xu; Yinglan Zhao; Xiaobo Cen
Journal:  Neuropsychopharmacology       Date:  2017-07-20       Impact factor: 7.853

Review 9.  Potential of GABAB Receptor Positive Allosteric Modulators in the Treatment of Alcohol Use Disorder.

Authors:  Paola Maccioni; Giancarlo Colombo
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

10.  Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats.

Authors:  M Scott Bowers; Billy T Chen; Jonathan K Chou; Megan P H Osborne; Justin T Gass; Ronald E See; Antonello Bonci; Patricia H Janak; M Foster Olive
Journal:  Psychopharmacology (Berl)       Date:  2007-09-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.